C9306 — Injection, telisotuzumab vedotin-tllv, 1 mg
C9306 is a HCPCS Level II code for injection, telisotuzumab vedotin-tllv, 1 mg. It belongs to the Outpatient Prospective Payment System section. It was terminated on December 31, 2025 and is not valid on new claims.
This code has been terminated
CMS terminated C9306 on December 31, 2025. It stays in the file as history — a claim you are auditing from before that date may legitimately carry it — but it must not appear on a new claim. The adjacent codes below are the usual place to look for its replacement.
Medicare coverage: Special coverage instructions apply
There are published conditions attached to this code. Check the applicable coverage policy before billing it: the code being valid is not the same as the service being covered.
From the coverage field of the CMS Alpha-Numeric HCPCS File, release 2026Q3-Jul. This states Medicare’s position on the code, not on your particular claim.
The CMS record for C9306
- Long descriptor
- Injection, telisotuzumab vedotin-tllv, 1 mg
- Short descriptor
- Telisotuzumab vedotin-tllv
- Added
- October 1, 2025
- Terminated
- December 31, 2025
- BETOS
- O1E
- Pricing indicator
- 53 — Other
The official wording. This is what the code means.
CMS's 28-character form, which is what shows up on a remittance advice.
When CMS introduced the code.
When CMS retired it.
Berenson-Eggers Type of Service — CMS's own analytic grouping.
Statute.
Codes adjacent to C9306
HCPCS has no hierarchy — related items simply sit next to each other in the numbering. If C9306 is not quite right, the correct code is very often within a few positions of it.
- C9290Injection, bupivacaine liposome, 1 mgterminated
- C9293Injection, glucarpidase, 10 units
- C9300Injection, indigotindisulfonate sodium, 1 mgterminated
- C9301Obecabtagene autoleucel, up to 400 million cd19 car-positive viable t cells, including leukapheresis and dose preparation procedures, per therapeutic doseterminated
- C9302Injection, zanidatamab-hrii, 2 mgterminated
- C9303Injection, zolbetuximab-clzb, 1 mgterminated
- C9304Injection, marstacimab-hncq, 0.5 mgterminated
- C9305Injection, nipocalimab-aahu, 3 mgterminated
- C9307Injection, linvoseltamab-gcpt, 1 mgterminated
- C9308Injection, carboplatin (avyxa), 1 mgterminated
- C9309Injection, onasemnogene abeparvovec-brve, per treatmentterminated
- C9310Injection, leucovorin calcium (avyxa), 1 mg
- C9349Puraply, and puraply antimicrobial, any type, per square centimeterterminated
- C9352Microporous collagen implantable tube (neuragen nerve guide), per centimeter length
- C9353Microporous collagen implantable slit tube (neurawrap nerve protector), per centimeter length
- C9354Acellular pericardial tissue matrix of non-human origin (veritas), per square centimeter
Questions about C9306
What is HCPCS code C9306?
C9306 is a HCPCS Level II code for injection, telisotuzumab vedotin-tllv, 1 mg. It sits in the Outpatient Prospective Payment System section.
Does Medicare cover C9306?
The CMS HCPCS file marks C9306 as "Special coverage instructions apply". There are published conditions attached to this code. Check the applicable coverage policy before billing it: the code being valid is not the same as the service being covered.
Is C9306 still valid?
No. C9306 was terminated on December 31, 2025 and should not be used on new claims.